1-(4-溴苄基)高哌嗪 | 690632-73-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-溴苄基)高哌嗪
• 中文别名: 1-(4-溴苄基)-1,4-二氮杂卓
• 英文名称: 1-(4-bromobenzyl)-1,4-diazepane
• 英文别名: 1-[(4-bromophenyl)methyl]-1,4-diazepane
• CAS: 690632-73-6
• 化学式: C₁₂H₁₇BrN₂
• 分子量: 269.184
• InChiKey: PUTBARDRYLXING-UHFFFAOYSA-N

物化性质

• 熔点：
  56-58 °C
• 沸点：
  140 °C
• 密度：
  1.308±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P301+P330+P331,P303+P361+P353,P363,P304+P340,P310,P321,P260,P264,P280,P305+P351+P338,P405,P501
• 危险品运输编号：
  2735
• 危险性描述：
  H314

SDS

Name:	1-(4-Bromobenzyl)-1 4-diazepane Material Safety Data Sheet
Synonym:	None Known
CAS:	690632-73-6

Section 1 - Chemical Product MSDS Name:1-(4-Bromobenzyl)-1 4-diazepane Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
690632-73-6	1-(4-Bromobenzyl)-1,4-diazepane	97+	unlisted

Hazard Symbols: C
Risk Phrases: 35

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes severe burns.
Potential Health Effects
Eye:
Causes severe eye burns.
Skin:
Causes severe burns.
Ingestion:
Causes severe digestive tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed. Extensive irrigation with water is required (at least 30 minutes).
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Discard contaminated shoes.
Use only with adequate ventilation.
Storage:
Store in a tightly closed container. Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 690632-73-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 140 deg C @ 0.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H17BrN2
Molecular Weight: 269.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 690632-73-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4-Bromobenzyl)-1,4-diazepane - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3275
Packing Group: II
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3275
Packing Group: II
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3275
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 35 Causes severe burns.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 690632-73-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 690632-73-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 690632-73-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1-氧代-1,3-二氢-异吲哚-2-基)-乙酸 、 1-(4-溴苄基)高哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以47%的产率得到2-(2-(4-(4-bromobenzyl)-1,4-diazepan-1-yl)-2-oxoethyl)isoindolin-1-one
  参考文献：
  名称：

  Synthesis and in Vivo Evaluation of [¹²³I]Melanin-Targeted Agents

  摘要：

  study reports the synthesis, [I-123]radiolabeling, and biological profile of a new series of iodinated compounds for potential translation to the corresponding [I-131]radiolabeled compounds for radionuclide therapy of melanoma. Radiolabeling was achieved via standard electrophilic iododestannylation in 60-90% radiochemical yield. Preliminary SPECT imaging demonstrated high and distinct tumor uptake of all compounds, as well as high tumor-to-background ratios compared to the literature compound [I-123]4 (ICF01012). The most favorable compounds ([I-123]20, [I-123]23, [I-123] 41, and [I-123]53) were selected for further biological investigation. Biodistribution studies indicated that all four compounds bound to melanin containing tissue with low in vivo deiodination; [I-123]20 and [I-123]53 in particular displayed high and prolonged tumor uptake (13% ID/g at 48 h). [I-123]53 had the most favorable overall profile of the cumulative uptake over time of radiosensitive organs. Metabolite analysis of the four radiotracers found [I-123]41 and [I-123]53 to be the most favorable, displaying high and prolonged amounts of intact tracer in melanin containing tissues, suggesting melanin specific binding. Results herein suggest that compound [I-123]53 displays favorable in vivo pharrnacokinetics and stability and hence is an ideal candidate to proceed with further preclinical [I-131] therapeutic evaluation.

  DOI：

  10.1021/acs.jmedchem.5b00777
• 作为产物：
  描述：

  1,4-二氮杂环庚烷-1-甲酸叔丁酯 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 32.0h， 生成 1-(4-溴苄基)高哌嗪
  参考文献：
  名称：

  Synthesis and in Vivo Evaluation of [¹²³I]Melanin-Targeted Agents

  摘要：

  study reports the synthesis, [I-123]radiolabeling, and biological profile of a new series of iodinated compounds for potential translation to the corresponding [I-131]radiolabeled compounds for radionuclide therapy of melanoma. Radiolabeling was achieved via standard electrophilic iododestannylation in 60-90% radiochemical yield. Preliminary SPECT imaging demonstrated high and distinct tumor uptake of all compounds, as well as high tumor-to-background ratios compared to the literature compound [I-123]4 (ICF01012). The most favorable compounds ([I-123]20, [I-123]23, [I-123] 41, and [I-123]53) were selected for further biological investigation. Biodistribution studies indicated that all four compounds bound to melanin containing tissue with low in vivo deiodination; [I-123]20 and [I-123]53 in particular displayed high and prolonged tumor uptake (13% ID/g at 48 h). [I-123]53 had the most favorable overall profile of the cumulative uptake over time of radiosensitive organs. Metabolite analysis of the four radiotracers found [I-123]41 and [I-123]53 to be the most favorable, displaying high and prolonged amounts of intact tracer in melanin containing tissues, suggesting melanin specific binding. Results herein suggest that compound [I-123]53 displays favorable in vivo pharrnacokinetics and stability and hence is an ideal candidate to proceed with further preclinical [I-131] therapeutic evaluation.

  DOI：

  10.1021/acs.jmedchem.5b00777

文献信息

• Design, synthesis and antibacterial evaluation of 2,4-disubstituted-6-thiophenyl-pyrimidines
  作者：Zhiyuan Fang、Sichao Zheng、Kin-Fai Chan、Wenchang Yuan、Qi Guo、Wenyu Wu、Hoi-Kui Lui、Yujing Lu、Yun-Chung Leung、Tak-Hang Chan、Kwok-Yin Wong、Ning Sun

  DOI：10.1016/j.ejmech.2018.10.039

  日期：2019.1

  development of novel antibacterial having a new mechanism of action. The small molecule-based inhibitors targeting at the cell division protein FtsZ has been recognized as a promising approach to search for new antibacterial with high potency. In the present study, a series of novel 2,4-disubstituted-6-thiophenyl-pyrimidine derivatives were synthesized and their antibacterial activities against clinically

  耐多药细菌感染的发病率增加促使具有新作用机制的新型抗菌剂的开发。靶向细胞分裂蛋白FtsZ的基于小分子的抑制剂已被认为是寻找具有高效力的新型抗菌药物的有前途的方法。在本研究中，合成了一系列新颖的2,4-二取代-6-硫代苯基-嘧啶衍生物，并研究了它们对临床相关病原体的抗菌活性。这些化合物对MRSA和VRE具有强大的抗菌活性。化合物Bb2对MRSA和VRE的抗菌活性（MIC值：2μg/ mL）比甲氧西林和万古霉素强。从体外和体内结果，发现Bb2抑制GTP酶活性和FtsZ聚合。该化合物能够通过与FtsZ的GTP结合位点相互作用来抑制细菌细胞分裂，从而引起细胞死亡。此外，发现金黄色葡萄球菌对甲氧西林产生抗药性，但对Bb2不产生抗药性，这在我们的抗药性产生实验中得到了证明。
• THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
  申请人：NV reMYND

  公开号：EP1981504B1

  公开（公告）日：2010-07-21
• THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES
  申请人：NV Remynd

  公开号：EP2094677A1

  公开（公告）日：2009-09-02
• THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20090054410A1

  公开（公告）日：2009-02-26

  This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives.
• US7960556B2
  申请人：——

  公开号：US7960556B2

  公开（公告）日：2011-06-14